Pliant Therapeutics, Inc. (PLRX) stock
PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.66+0.00 (+0.12%)
Close on Nov 18, 2026Market cap $40.93MP/E –Yield 0.00%
Pliant Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Pliant Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$70.90M. For fiscal 2025 it was -$128.71M. The highest annual figure on record is -$3.71M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$128.71M | – |
| FY2024 | Dec 31, 2024 | -$159.35M | – |
| FY2023 | Dec 31, 2023 | -$117.28M | – |
| FY2022 | Dec 31, 2022 | -$96.39M | – |
| FY2021 | Dec 31, 2021 | -$77.40M | – |
| FY2020 | Dec 31, 2020 | -$38.80M | – |
| FY2019 | Dec 31, 2019 | -$3.71M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.80M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.79M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.08M | – |
| Q2 FY2025 | Jun 30, 2025 | -$40.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$49.13M | – |
| Q4 FY2024 | Dec 31, 2024 | -$47.87M | – |
| Q3 FY2024 | Sep 30, 2024 | -$33.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$46.55M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.76M | – |
| Q4 FY2023 | Dec 31, 2023 | -$25.16M | – |
| Q3 FY2023 | Sep 30, 2023 | -$36.32M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.36M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.44M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.41M | – |
| Q3 FY2022 | Sep 30, 2022 | -$19.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.65M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.14M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.46M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.99M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.04M | -367.7% |
| Q1 FY2021 | Mar 31, 2021 | -$13.91M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.07M | -146.7% |
| Q3 FY2020 | Sep 30, 2020 | -$16.12M | – |
| Q2 FY2020 | Jun 30, 2020 | $7.49M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.10M | – |
| Q4 FY2019 | Dec 31, 2019 | $36.56M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.92M | – |
See a number that looks wrong?